23 related articles for article (PubMed ID: 3512115)
1. Enhancement of β-Lactam-Mediated Killing of Gram-Negative Bacteria by Lysine Hydrochloride.
Hong S; Su S; Gao Q; Chen M; Xiao L; Cui R; Guo Y; Xue Y; Wang D; Niu J; Huang H; Zhao X
Microbiol Spectr; 2023 Aug; 11(4):e0119823. PubMed ID: 37310274
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow purging with mafosfamide--a critical survey.
Sindermann H; Peukert M; Hilgard P
Blut; 1989 Nov; 59(5):432-41. PubMed ID: 2684298
[TBL] [Abstract][Full Text] [Related]
3. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
4. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
[TBL] [Abstract][Full Text] [Related]
6. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095
[TBL] [Abstract][Full Text] [Related]
7. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
Bremner DN; McCormick JS; Thomson JW
Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
[No Abstract] [Full Text] [Related]
8. Experimental toxicology of ASTA Z 7557 (INN mafosfamide).
Pohl J; Hilgard P; Jahn W; Zechel HJ
Invest New Drugs; 1984; 2(2):201-6. PubMed ID: 6469515
[TBL] [Abstract][Full Text] [Related]
9. Antineoplastic activity of ASTA Z 7557 (NSC-345842, INN mafosfamide) on transplantable murine tumors.
Atassi G; Hilgard P; Pohl J
Invest New Drugs; 1984; 2(2):169-73. PubMed ID: 6469511
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.
Brock N
Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of cyclohexylamine and lysine salt of mafosfamide.
Abele R; Aapro MS; Haefliger JM; Alberto P
Cancer Chemother Pharmacol; 1986; 16(2):182-3. PubMed ID: 3512115
[TBL] [Abstract][Full Text] [Related]
12. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
